产品
编 号：F412791
分子式：C16H17N5O7S2
分子量：455.47
分子式：C16H17N5O7S2
分子量：455.47
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
100mg
400
In-stock
250mg
800
In-stock
500mg
1080
In-stock
结构图
CAS No: 63527-52-6
产品详情
生物活性：
Cefotaxime, a β-lactamase stable cephalosporin and a third-generation cephalosporin antibiotic, possesses broad-spectrum antibiotic activity against numerous Gram-positive and Gram-negative bacteria.
体内研究：
The combination of ciprofloxacin and cefotaxime is more effective in clearing V. vulnificus in vivo than previously used regimens.Animal Model:Female, specific pathogen free, 8-week-old BALB/c mice.
Dosage:30 mg/kg.
Administration:IP every 6 h.
Result:The viable bacterial counts in liver were lower in mice treated with cefotaxime-plus-ciprofloxacin than in those treated with cefotaxime alone (P<0.001 at 24 h and 48 h, each).
体外研究：
Cefotaxime exhibits an MIC of 0.0625 mg/L for V. vulnificus CMCP6.
Cefotaxime, a β-lactamase stable cephalosporin and a third-generation cephalosporin antibiotic, possesses broad-spectrum antibiotic activity against numerous Gram-positive and Gram-negative bacteria.
体内研究：
The combination of ciprofloxacin and cefotaxime is more effective in clearing V. vulnificus in vivo than previously used regimens.Animal Model:Female, specific pathogen free, 8-week-old BALB/c mice.
Dosage:30 mg/kg.
Administration:IP every 6 h.
Result:The viable bacterial counts in liver were lower in mice treated with cefotaxime-plus-ciprofloxacin than in those treated with cefotaxime alone (P<0.001 at 24 h and 48 h, each).
体外研究：
Cefotaxime exhibits an MIC of 0.0625 mg/L for V. vulnificus CMCP6.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备